We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+15.71%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$2.12B
AUM Growth
+$363M
Cap. Flow
+$161M
Cap. Flow %
7.62%
Top 10 Hldgs %
72.29%
Holding
40
New
2
Increased
23
Reduced
1
Closed
1

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$40.4M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$37.6M
3
EPZM
Epizyme, Inc
EPZM
+$23.4M
4
ALGN icon
Align Technology
ALGN
+$18.6M
5
AIMT
Aimmune Therapeutics
AIMT
+$16.3M

Top Sells

Rank Stock Value
1
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$33.4M
2
PGEN icon
Precigen
PGEN
+$8.42K

Sector Composition

Rank Sector Weight
1 Healthcare 95.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIRX
26
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$4.77M 0.23%
33,214
– –
ALIM
27
DELISTED
Alimera Sciences
ALIM
$4.22M 0.2%
200,920
– –
TLPH icon
28
Talphera
TLPH
$72.7M
$3.25M 0.15%
51,636
– –
DRNA
29
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$1.64M 0.08%
481,519
+323,240
+204% +$910K
CYTK icon
30
Cytokinetics
CYTK
$10.5B
$1.59M 0.08%
123,686
– –
ACGN
31
DELISTED
Aceragen Inc
ACGN
$1.52M 0.07%
4,537
– –
CEMP
32
DELISTED
Cempra, Inc.
CEMP
$1.28M 0.06%
340,320
– –
TRVN
33
DELISTED
Trevena, Inc.
TRVN
$1.25M 0.06%
+546
New +$1.86M
PGEN icon
34
Precigen
PGEN
$2.45B
$830K 0.04%
41,900
-377
-0.9% -$8.42K
SPHS
35
DELISTED
Sophiris Bio, Inc.
SPHS
$699K 0.03%
247,000
– –
OCGN icon
36
Ocugen
OCGN
$475M
$524K 0.02%
5,049
– –
ZGNX
37
DELISTED
Zogenix, Inc.
ZGNX
$320K 0.02%
29,500
– –
ARCT icon
38
Arcturus Therapeutics
ARCT
$216M
$311K 0.01%
38,970
– –
SLNO
39
DELISTED
Soleno Therapeutics
SLNO
$301K 0.01%
+5,650
New +$333K
ARIA
40
DELISTED
Ariad Pharmaceuticals Inc
ARIA
– –
-2,682,017
Closed -$33.4M
1
2

Similar funds

AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
PCM
Primavera Capital Management George Town, Cayman Islands $648M AUM 6.1% 1-Year Est. Return
HCM
Huber Capital Management El Segundo, California $647M AUM 24.91% 1-Year Est. Return
ACM
Arosa Capital Management Miami Beach, Florida $660M AUM 210.26% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Palo Alto Investors's Q1 2017 Portfolio in Review

As of Q1 2017, Palo Alto Investors held 40 positions worth $2.12B, up 21% from $1.75B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Palo Alto Investors deployed $161M of net new capital in Q1 2017, opening 2 new positions and adding to 23 existing holdings. Its largest new stake was Trevena, Inc.: 546 shares worth $1.25M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 93% a quarter earlier.

On the sell side, the largest reduction was Precigen, an estimated $8.42K trimmed.

  • Palo Alto Investors's largest Q1 2017 buy was Trevena, Inc.: 546 shares worth $1.25M.
  • Palo Alto Investors added most to Alexion Pharmaceuticals in Q1 2017, an estimated $40.4M increase.
  • Palo Alto Investors's biggest Q1 2017 reduction was Precigen, cutting an estimated $8.42K.
  • Palo Alto Investors fully exited Ariad Pharmaceuticals Inc in Q1 2017, selling an estimated $33.4M.
  • Palo Alto Investors's ten largest holdings make up 72% of its $2.12B portfolio in Q1 2017.
  • Palo Alto Investors opened 2 new positions and closed 1 in Q1 2017.
  • Palo Alto Investors's portfolio value rose 21% quarter-over-quarter to $2.12B.

Based on Palo Alto Investors's 13F filing for Q1 2017, filed 15 May 2017.